Sanara MedTech faces securities fraud probe after $31.2M loss and program shutdown.

Sanara MedTech Inc. is under investigation by the Schall Law Firm for potential securities law violations after it announced the discontinuation of its Tissue Health Plus program and reported a $31.2 million net loss from discontinued operations, including a $26.5 million charge related to the program. The company's stock dropped 24.7% following the announcement. The investigation focuses on whether Sanara made false or misleading statements or failed to disclose important information to investors. Shareholders who suffered losses are encouraged to contact the law firm to discuss their rights.